NCT02974504View on ClinicalTrials.gov

Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)

PHASE4CompletedINTERVENTIONAL

Enrollment

207

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions

Type2 Diabetes

Interventions

DRUG

evogliptin

evogliptin 5mg tablet qd + placebo tablet matching to linagliptin 5mg

DRUG

Linagliptin

linagliptin 5 mg tablet qd + placebo tablet matching to evogliptin 5mg

Trial Locations (1)

Unknown

Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT02974504 - Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN) | Biotech Hunter | Biotech Hunter